Education
About Us
Working with TipRanks
Follow Us
Crinetics Pharma (CRNX)
:CRNX
CRNX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$24.10 - $62.53
Previous CloseN/A
Volume214.21K
Average Volume (3M)847.27K
Market Cap
$2.67B
Enterprise Value$1.90B
Total Cash (Recent Filing)$1.27B
Total Debt (Recent Filing)$50.82M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Nov 06, 2025EPS Estimate
-1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding93,680,130
10 Day Avg. Volume929,566
30 Day Avg. Volume847,273
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue2.50K
Enterprise Value/Gross Profit271.26K
Enterprise Value/Ebitda-5.08
Forecast
1Y Price Target
$72.20Price Target Upside158.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
Product LaunchThe potential launch of paltusotine in acromegaly could transform the company into a commercial organization.
Regulatory ProgressEx-US launch activities have seen progress, with the EMA validating the MMA filing for approval in Europe and granting paltusotine Orphan Drug Designation.
Bears Say
Investor SentimentThere seems to be a significant investor disconnect, stemming from safety concerns with atumelnant in congenital adrenal hyperplasia and a perceived catalyst desert in the future.
Safety ConcernsSafety concerns with atumelnant in congenital adrenal hyperplasia have contributed to a significant investor disconnect.
Crinetics Pharmaceuticals News
CRNX FAQ
What was Crinetics Pharma’s price range in the past 12 months?
Crinetics Pharma lowest stock price was $24.10 and its highest was $62.53 in the past 12 months.
What is Crinetics Pharma’s market cap?
Crinetics Pharma’s market cap is $2.67B.
When is Crinetics Pharma’s upcoming earnings report date?
Crinetics Pharma’s upcoming earnings report date is Nov 06, 2025 which is in 90 days.
How were Crinetics Pharma’s earnings last quarter?
Crinetics Pharma released its earnings results on Aug 07, 2025. The company reported -$1.23 earnings per share for the quarter, missing the consensus estimate of -$1.082 by -$0.148.
Is Crinetics Pharma overvalued?
According to Wall Street analysts Crinetics Pharma’s price is currently Undervalued.
Does Crinetics Pharma pay dividends?
Crinetics Pharma does not currently pay dividends.
What is Crinetics Pharma’s EPS estimate?
Crinetics Pharma’s EPS estimate is -1.22.
How many shares outstanding does Crinetics Pharma have?
Crinetics Pharma has 93,680,130 shares outstanding.
What happened to Crinetics Pharma’s price movement after its last earnings report?
Crinetics Pharma reported an EPS of -$1.23 in its last earnings report, missing expectations of -$1.082. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Crinetics Pharma?
Currently, no hedge funds are holding shares in CRNX
Crinetics Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$72.20 (158.97% Upside)
$72.20 (158.97% Upside)
Blogger Sentiment
Bullish
CRNX Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 494.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 13.7%
Last 30 Days ▲ 13.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.27%
12-Months-Change
Fundamentals
Return on Equity
-30.84%
Trailing 12-Months
Asset Growth
39.17%
Trailing 12-Months
Company Description
Crinetics Pharma
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
CRNX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Crinetics Pharmaceuticals, Inc. with significant progress in regulatory approvals, strong financial positioning, and preparations for the commercial launch of paltusotine. However, the decrease in revenue and increase in operating expenses present challenges.View all CRNX earnings summariesCRNX Stock 12 Month Forecast
Average Price Target
$72.20
▲(158.97% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Viking Therapeutics
―
Apellis Pharmaceuticals
―
Scholar Rock Holding
―
Immunovant
―
Ownership Overview
2.09% Insiders
40.85% Mutual Funds
0.05% Other Institutional Investors
40.29% Public Companies and
Individual Investors